MA31143B1 - Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree - Google Patents
Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioreeInfo
- Publication number
- MA31143B1 MA31143B1 MA32042A MA32042A MA31143B1 MA 31143 B1 MA31143 B1 MA 31143B1 MA 32042 A MA32042 A MA 32042A MA 32042 A MA32042 A MA 32042A MA 31143 B1 MA31143 B1 MA 31143B1
- Authority
- MA
- Morocco
- Prior art keywords
- biological activity
- modified soluble
- improved biological
- fusion proteins
- soluble fgf
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title abstract 2
- 102000009109 Fc receptors Human genes 0.000 title 1
- 108010087819 Fc receptors Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 108091008794 FGF receptors Proteins 0.000 abstract 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des fusions de Fc de récepteur de FGF soluble modifié, comprenant une fusion d'un fragment ou domaine soluble de la partie de récepteur de FGF (fraction de ciblage ou de liaison) avec une région Fc d'une partie immunoglobuline (fraction de fonction effectrice), ayant une activité biologique améliorée comprenant les activités ADCC/CDC, sur des compositions les contenant et sur un procédé de fabrication de telles molécules de fusion de Fc de récepteur de FGF soluble modifié.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06291824 | 2006-11-28 | ||
EP07290042 | 2007-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31143B1 true MA31143B1 (fr) | 2010-02-01 |
Family
ID=39431092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32042A MA31143B1 (fr) | 2006-11-28 | 2009-06-24 | Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree |
Country Status (33)
Country | Link |
---|---|
US (3) | US8119770B2 (fr) |
EP (1) | EP2092069B2 (fr) |
JP (1) | JP2010510801A (fr) |
KR (1) | KR20090102769A (fr) |
AR (1) | AR063975A1 (fr) |
AT (1) | ATE509106T1 (fr) |
AU (1) | AU2007326985C1 (fr) |
BR (1) | BRPI0719290A2 (fr) |
CA (1) | CA2668932A1 (fr) |
CL (1) | CL2007003411A1 (fr) |
CO (1) | CO6190564A2 (fr) |
CR (1) | CR10777A (fr) |
CY (1) | CY1112435T1 (fr) |
DK (1) | DK2092069T3 (fr) |
EA (1) | EA018700B1 (fr) |
EC (1) | ECSP099361A (fr) |
GT (1) | GT200900137A (fr) |
HR (1) | HRP20110503T1 (fr) |
IL (1) | IL198480A0 (fr) |
MA (1) | MA31143B1 (fr) |
MX (1) | MX2009005692A (fr) |
MY (1) | MY145914A (fr) |
NI (1) | NI200900097A (fr) |
NO (1) | NO20092414L (fr) |
PE (1) | PE20081250A1 (fr) |
PL (1) | PL2092069T3 (fr) |
PT (1) | PT2092069E (fr) |
RS (1) | RS51911B (fr) |
SI (1) | SI2092069T1 (fr) |
SV (1) | SV2009003272A (fr) |
TN (1) | TN2009000184A1 (fr) |
TW (1) | TW200839012A (fr) |
WO (1) | WO2008065543A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2536918A1 (fr) | 2003-08-26 | 2005-03-03 | Leland Shapiro | Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine |
EP2083081A1 (fr) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR |
CA2732449A1 (fr) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Muteines de region acide de domaine extracellulaire de fgfr |
EP2478003A4 (fr) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | Méthodes de croissance des cheveux utilisant les domaines extracellulaires de fgfr4 |
PL2498799T3 (pl) | 2009-11-13 | 2017-03-31 | Five Prime Therapeutics, Inc. | Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2 |
US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
AU2015258172B2 (en) * | 2010-11-15 | 2017-01-12 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
EA025828B1 (ru) * | 2010-11-15 | 2017-02-28 | Файв Прайм Терапьютикс, Инк. | Комбинированная терапия внеклеточным доменом fgfr1 |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
KR20130132880A (ko) | 2010-12-23 | 2013-12-05 | 사노피 | 간암의 치료에 사용하기 위한 robo1-fc 융합 단백질 |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
CN102219859B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
KR102103476B1 (ko) * | 2011-06-24 | 2020-04-23 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
CN107823630A (zh) * | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
EP2802653A4 (fr) | 2012-01-10 | 2015-09-02 | Univ Colorado Regents | Compositions de molécules de fusion de l'alpha-1 antitrypsine, procédés et utilisations associés |
KR20160002681A (ko) | 2013-01-16 | 2016-01-08 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 |
EP2964260A2 (fr) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Méthodes de traitement et de prévention de la résistance à un médicament d'un cancer |
CA2902530C (fr) * | 2013-03-11 | 2023-05-09 | Genzyme Corporation | Conjugaison anticorps-medicament specifique d'un site par glyco-ingenierie |
US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
WO2014190147A2 (fr) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Méthodes de traitement du cancer |
LT3708583T (lt) | 2013-08-01 | 2022-04-11 | Five Prime Therapeutics, Inc. | Afukozilinti anti-fgfr2iiib antikūnai |
EP4015535A1 (fr) | 2014-03-19 | 2022-06-22 | Genzyme Corporation | Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site |
US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
TWI791422B (zh) * | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
JP6967578B2 (ja) * | 2017-11-30 | 2021-11-17 | グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド | 免疫チェックポイント阻害剤pd−1及びpd−l1に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質 |
PE20212075A1 (es) * | 2018-01-26 | 2021-10-26 | Genentech Inc | PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288856A (en) | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US5288855A (en) * | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
DE69033109T2 (de) | 1989-07-06 | 1999-11-18 | The Regents Of The University Of California, Oakland | Rezeptoren für fibroblasten-wachstumsfaktoren |
WO1991017183A1 (fr) * | 1990-04-27 | 1991-11-14 | Takeda Chemical Industries, Ltd. | Proteines presentant une activite de recepteur de facteur de croissance de fibroblaste |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
AU662107B2 (en) | 1990-07-06 | 1995-08-24 | Aventis Pharmaceuticals Inc. | Fibroblast growth factor receptors |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
US6656728B1 (en) * | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US6612152B2 (en) * | 1999-05-01 | 2003-09-02 | James E. Keaton | Lifting, servicing, and diagnosing automobiles |
US6656738B1 (en) * | 1999-11-17 | 2003-12-02 | Bae Systems Integrated Defense Solutions Inc. | Internal heater for preconcentrator |
EP1299535A2 (fr) * | 2000-06-30 | 2003-04-09 | Maxygen Aps | Polypeptides glycosyles a extension peptidique |
JP4290423B2 (ja) | 2000-10-06 | 2009-07-08 | 協和発酵キリン株式会社 | 抗体組成物を生産する細胞 |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
EP1498491A4 (fr) * | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
EP3150630A1 (fr) * | 2002-09-27 | 2017-04-05 | Xencor Inc. | Variantes fc optimisées et leurs procédés de génération |
CA2525969A1 (fr) | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci |
WO2005035741A1 (fr) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Cellule a genome modifie |
DE102004022895A1 (de) | 2004-05-10 | 2005-12-08 | Adam Opel Ag | Schallabsorbierendes Verkleidungselement |
CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
WO2006047350A2 (fr) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | Variants d'immunoglobuline igg a fonction effectrice optimisee |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
EP1746161A1 (fr) * | 2005-07-20 | 2007-01-24 | Cytheris | IL-7 glycosylée, préparation et utilisations |
EP2083081A1 (fr) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
-
2007
- 2007-11-27 CL CL200703411A patent/CL2007003411A1/es unknown
- 2007-11-27 AR ARP070105241A patent/AR063975A1/es not_active Application Discontinuation
- 2007-11-27 PE PE2007001663A patent/PE20081250A1/es not_active Application Discontinuation
- 2007-11-28 TW TW096145220A patent/TW200839012A/zh unknown
- 2007-11-28 RS RS20110324A patent/RS51911B/en unknown
- 2007-11-28 WO PCT/IB2007/004354 patent/WO2008065543A2/fr active Application Filing
- 2007-11-28 DK DK07866627.8T patent/DK2092069T3/da active
- 2007-11-28 KR KR1020097013421A patent/KR20090102769A/ko not_active Application Discontinuation
- 2007-11-28 AU AU2007326985A patent/AU2007326985C1/en not_active Ceased
- 2007-11-28 JP JP2009538805A patent/JP2010510801A/ja active Pending
- 2007-11-28 EP EP07866627.8A patent/EP2092069B2/fr active Active
- 2007-11-28 MX MX2009005692A patent/MX2009005692A/es active IP Right Grant
- 2007-11-28 BR BRPI0719290-8A patent/BRPI0719290A2/pt not_active IP Right Cessation
- 2007-11-28 CA CA002668932A patent/CA2668932A1/fr not_active Abandoned
- 2007-11-28 SI SI200730682T patent/SI2092069T1/sl unknown
- 2007-11-28 PT PT07866627T patent/PT2092069E/pt unknown
- 2007-11-28 EA EA200970515A patent/EA018700B1/ru not_active IP Right Cessation
- 2007-11-28 US US12/515,463 patent/US8119770B2/en not_active Expired - Fee Related
- 2007-11-28 MY MYPI20092137A patent/MY145914A/en unknown
- 2007-11-28 PL PL07866627T patent/PL2092069T3/pl unknown
- 2007-11-28 AT AT07866627T patent/ATE509106T1/de active
-
2009
- 2009-04-30 IL IL198480A patent/IL198480A0/en unknown
- 2009-05-07 CR CR10777A patent/CR10777A/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000184A patent/TN2009000184A1/fr unknown
- 2009-05-20 GT GT200900137A patent/GT200900137A/es unknown
- 2009-05-25 EC EC2009009361A patent/ECSP099361A/es unknown
- 2009-05-26 SV SV2009003272A patent/SV2009003272A/es unknown
- 2009-05-26 CO CO09053830A patent/CO6190564A2/es not_active Application Discontinuation
- 2009-05-27 NI NI200900097A patent/NI200900097A/es unknown
- 2009-06-24 MA MA32042A patent/MA31143B1/fr unknown
- 2009-06-24 NO NO20092414A patent/NO20092414L/no not_active Application Discontinuation
-
2011
- 2011-07-06 HR HR20110503T patent/HRP20110503T1/hr unknown
- 2011-08-09 CY CY20111100764T patent/CY1112435T1/el unknown
-
2012
- 2012-01-11 US US13/348,297 patent/US8481487B2/en not_active Expired - Fee Related
-
2013
- 2013-06-28 US US13/931,184 patent/US20140030265A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31143B1 (fr) | Proteines de fusion recepteur du fgf/fc solubles modifiees presentant une activite biologique amelioree | |
JP6734227B2 (ja) | 抗cd276抗体(b7h3) | |
US11845793B2 (en) | Anti-ROR1 antibodies | |
JP2023153895A (ja) | 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用 | |
EP1189931B1 (fr) | Composes de peptide se liant a her2 | |
WO2004019878A3 (fr) | Adzymes et leurs utilisations | |
CN104105711B (zh) | 单链抗体及其他异多聚体 | |
ATE466886T1 (de) | Adzyme und deren verwendungen | |
KR101882366B1 (ko) | 온코스타틴 m 수용체 항원 결합 단백질 | |
PL374587A1 (en) | Pharmaceutical compositions directed to erb-b1 receptors | |
KR20070073886A (ko) | 독성이 감소된 치료제 | |
TNSN07394A1 (en) | Antibodies to myostatin | |
CN115819588A (zh) | 新型抗cd19抗体 | |
US20230265206A1 (en) | Antibodies against cdcp1 for the treatment and detection of cancer | |
Jureczek et al. | An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells | |
JP2019527033A (ja) | 抗第IX因子Padua抗体 | |
Akbari et al. | Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A | |
CN108290950A (zh) | 抗cd95l抗体 | |
WO2008060814A3 (fr) | ANTICORPS DIRIGÉS CONTRE IL-13Rα1 ET LEURS UTILISATIONS | |
UY30749A1 (es) | Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada | |
CN114144429B (zh) | 针对pd-1和lag-3的双特异性抗体 | |
CN117715942A (zh) | 使用抗体-寡核苷酸缀合物的增强的靶向 | |
Albone et al. | Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus | |
CN117279664A (zh) | Folr1结合剂、其偶联物及其使用方法 | |
TW202233680A (zh) | 具有增加的選擇性之多靶向性雙特異性抗原結合分子 |